KYMR vs. TEVA: Kymera Therapeutics vs. Teva Pharmaceutical Stock Comparison

Company Profile

Kymera Therapeutics (KYMR) and Teva Pharmaceutical (TEVA) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but KYMR is classified in Biotechnology while TEVA is classified in Pharmaceuticals.

Teva Pharmaceutical (TEVA) has more than two decades of public-market history since February 16, 1982, whereas Kymera Therapeutics (KYMR) listed on August 21, 2020 and has a much shorter record to draw on.

Kymera Therapeutics (KYMR) trades as ordinary local shares, while Teva Pharmaceutical (TEVA) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Kymera Therapeutics (KYMR) reports a negative ROE of -27.29%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Teva Pharmaceutical (TEVA) reports 6.65%, ranking against industry peers normally.

Both Kymera Therapeutics (KYMR) at 0.00% and Teva Pharmaceutical (TEVA) at 2.94% keep about the typical share of revenue as profit for their industries — neither bottom line stands out from peers.

Kymera Therapeutics (KYMR) reports a negative operating margin of -396.04%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Teva Pharmaceutical (TEVA) reports 27.40%, ranking against industry peers normally.

Profitability Metrics

Growth

Teva Pharmaceutical (TEVA) at 4.31% is around its peer norm for revenue growth, while Kymera Therapeutics (KYMR) at -16.70% drops into the bottom quartile, signaling weaker demand or pricing momentum.

Neither Kymera Therapeutics (KYMR) nor Teva Pharmaceutical (TEVA) reports a EPS growth value for this period, so a direct comparison isn't possible.

Growth Metrics

Financial Strength

Kymera Therapeutics (KYMR) at 11.13 keeps current ratio within its industry’s typical mid-range, while Teva Pharmaceutical (TEVA) at 0.95 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for TEVA.

Kymera Therapeutics (KYMR) at 0.05 is near its industry mid-range for debt-to-equity ratio, while Teva Pharmaceutical (TEVA) at 2.13 sits above its benchmark range, pointing to a heavier debt load relative to equity.

Financial Strength Metrics

Dividends

Neither Kymera Therapeutics (KYMR) nor Teva Pharmaceutical (TEVA) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither Kymera Therapeutics (KYMR) nor Teva Pharmaceutical (TEVA) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: Teva Pharmaceutical (TEVA) trades at 99.09 times trailing earnings, ranked against its peers, while Kymera Therapeutics (KYMR) has no P/E ratio this period.

Teva Pharmaceutical (TEVA) at 2.89 sits in the cheaper P/S ratio quartile while Kymera Therapeutics (KYMR) at 110.00 prices above its industry range — a wide gap in sales valuation between them.

Teva Pharmaceutical (TEVA) at 6.23 is valued about in line with its industry on P/B ratio, while Kymera Therapeutics (KYMR) at 6.96 carries an above-peer premium to book — KYMR is pricier on assets.

Valuation Metrics